PLANT BIOLOGY
ANIMAL BIOLOGY
SUBSCRIPTION
E-SUBSCRIPTION
 
MAP
MAIN PAGE

 

 

 

 

Chernyshev R.S., Shotin A.R., Igolkin A.S., Morozova E.O., Romenskaya D.V., Sprygin A.V., Mazloum A. Advancements and challenges in porcine genetically engineered vaccines (review). Sel'skokhozyaistvennaya Biologiya [Agricultural Biology], 2025,Vol. 60, № 2, p. 245-270.
(how to cite this article)

doi: 10.15389/agrobiology.2025.2.245eng

UDC: 636.4:619:578:615.371:577.2

Acknowledgements:
Supported financially by a grant from the Ministry of Science and Higher Education of the Russian Federation for the individual activities of the Federal Scientific and Technical Program for the Development of Genetic Technologies for 2019-2027 (Agreement No. 075-15-2021-1054)

 

ADVANCEMENTS AND CHALLENGES IN PORCINE GENETICALLY ENGINEERED VACCINES (review)

R.S. Chernyshev, A.R. Shotin, A.S. Igolkin, E.O. Morozova, D.V. Romenskaya, A.V. Sprygin✉, A. Mazloum

Federal Centre for Animal Health, Yuryevets microdistrict, Vladimir Province, Vladimir, 600901 Russia, e-mail  сhernishev_rs@arriah.ru (✉ corresponding author), shotin@arriah.ru, igolkin_as@arriah.ru, morozova_eo@arriah.ru, romenskaya@arriah.ru, sprygin@arriah.ru, mazlum@arriah.ru

ORCID:
Chernyshev R.S. orcid.org/0000-0003-3604-7161
Romenskaya D.V. orcid.org/0000-0002-2443-1898
Shotin A.R. orcid.org/0000-0001-9884-1841
Sprygin A.V. orcid.org/0000-0001-5982-3675
Igolkin A.S. orcid.org/0000-0002-5438-8026
Mazloum A. orcid.org/0000-0002-5982-8393
Morozova E.O. orcid.org/0000-0002-0955-9586

Final revision received October 26, 2023

Accepted November 13, 2023

Due to the high rate of development of the pig breeding industry both in the Russian Federation and abroad, the veterinary industry requires vaccines are safe for humans and the environment. A number of limitations of live midified and inactivated vaccines, discussed in the review, give advantage to the development and implementation of genetically engineered vaccines. They are divided into two large groups: laboratory-attenuated vaccines obtained by modifying the genome of the pathogen, and recombinant vaccines. The latter include subunit vaccines based on recombinant proteins, as well as live vector, DNA, and RNA vaccines. Possible ways of modifying the genome of viruses by homologous recombination, using meganucleases, "zinc fingers" (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR/Cas9 technology are described (S.H. Khan, 2019; Fabricci M. et al., 2020; Mazloum A. c et al., 2023). The expression of recombinant proteins is becoming possible in various systems: bacterial, produced by Escherichia coli, baculovirus, synthesizing proteins in insect cell cultures, yeast using Saccharomyces cerevisiae and Pichia pastoris (M. Karbalaei et al., 2020). The introduction of vector-based vaccines based on heterologous viruses (human adenovirus 5, avirulent herpesviruses, etc.) will help solve the problem of local and cell-mediated immunity to pathogens (J.L. Palgen et al., 2021). The main limiting factor in the use of DNA and RNA vaccines is the lack of a highly efficient method of delivering genetic material to target cells (T. Lee et al., 2022). Despite all the advantages of genetically engineered vaccines, their development, production and introduction into veterinary practice are limited due to the high cost, insufficient affinity and avidity of virus neutralizing antibodies, low antibody titer, and incomplete protection of animals during challenging. Despite the shortcomings, the development and registration of genetically engineered vaccines against infectious diseases of pigs in the world continues. Thus, the review presents and discusses existing developments and registered vaccines against African swine fever (M.V. Borca et al., 2020), pseudorabies (X. Liang et al., 2016), classical swine fever (S. Blome et al., 2017), porcine parvovirus (B. Garcia-Morante et al., 2020), coronavirus (X. Yuan et al., 2015) and circovirus (C. Park et al., 2017), porcine reproductive and respiratory syndrome (J. Cui et al., 2020). It is concluded that genetically modified viruses with a deficiency of genes encoding virulence factors are the most promising for the prevention of African swine fever, pseudorabies and porcine reproductive and respiratory syndrome. Subunit vaccines provide enhanced immunity against porcine parvovirus and circovirus. In turn, the possibilities of vector vaccines are most feasible in the fight against classical swine fever and porcine coronaviruses. In addition, the importance of genetically engineered vaccines lies in the formation of group immunity of swine populations to infectious diseases of viral etiology, and in the implementation of a strategy for differentiating infected from vaccinated animals (DIVA).  

Keywords: genetic engineering, subunit vaccines, vector vaccines, DNA vaccines, CRISPR/Cas9, African swine fever, classical swine fever, Aujeszky’s disease, porcine circoviruses, porcine coronaviruses, porcine reproductive and respiratory syndrome, porcine parvovirus, DIVA strategy.

 

REFERENCES

  1. Prodovol’stvennaya i sel’skokhozyaystvennaya organizatsiya Ob’‘edinennykh natsiy [Food and Agriculture Organization of the United Nations]. FAOSTAT. Rezhim dostupa: https://www.fao.org/faostat/ru/#data/QCL. Data obrashcheniya: 28.04.2025 (in Russ.).
  2. Mikhaylova O.A. Vestnik agrarnoy nauki, 2018, 1(70): 36-45 CrossRef (in Russ.).
  3. Bigras-Poulin M., Barfod K., Mortensen S., Greiner M.. Relationship of trade patterns of the Danish swine industry animal movements network to potential disease spread. Prev. Vet. Med., 2007, 80(2-3): 143-165 CrossRef
  4. Opriessnig T., Mattei A.A., Karuppannan A.K., Halbur P.G. Future perspectives on swine viral vaccines: where are we headed? Porcine Health Manag., 2021, 7(1): 1 CrossRef
  5. Minor P.D. Live attenuated vaccines: Historical successes and current challenges. Virology, 2015, 479-480: 379-392 CrossRef
  6. Chua B.Y., Sekiya T., Jackson D.C. Opinion: making inactivated and subunit-based vaccines work. Viral Immunol., 2018, 31(2): 150-158 CrossRef
  7. Martins C.L., Lawman M.J., Scholl T., Mebus C.A., Lunney J.K. African swine fever virus specific porcine cytotoxic T cell activity. Archives of Virology, 1993, 129: 211-225 CrossRef
  8. Escribano J.M., Galindo I., Alonso C. Antibody-mediated neutralization of African swine fever virus: myths and facts. Virus Research, 2013, 173(1): 101-109 CrossRef
  9. Dertzbaugh M.T. Genetically engineered vaccines: an overview. Plasmid, 1998, 39(2): 100-113 CrossRef
  10. Smithies O., Gregg R.G., Boggs S.S., Koralewski M.A., Kucherlapati R.S. Insertion of DNA sequences into the human chromosomal β-globin locus by homologous recombination. Nature, 1985, 317(6034): 230-234 CrossRef
  11. Maeder M.L., Gersbach C.A. Genome-editing technologies for gene and cell therapy. Molecular Therapy, 2016, 24(3): 430-446 CrossRef
  12. Okoli A., Okeke M.I., Tryland M., Moens U. CRISPR/Cas9-Advancing orthopoxvirus genome editing for vaccine and vector development. Viruses, 2018, 10(1): 50 CrossRef
  13. Goossens M., Pauwels K., Willemarck N., Breyer D. Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara (MVA)-based vectors. Curr. Gene Ther., 2013, 13(6): 413-420 CrossRef
  14. Fabricci M., Evangelou C. The revolution of the CRISPR-CAS9 system. CRISPR BIOTECH ENGINEERING, the United Kingdom, 2020.
  15. Khan S.H. Genome-editing technologies: concept, pros, and cons of various genome-editing techniques and bioethical concerns for clinical application. Molecular Therapy-Nucleic Acids, 2019, 16: 326-334 CrossRef
  16. Mazloum A., Karagyaur M., Chernyshev R., vanSchalkwyk A., Jun M., Qiang F., Sprygin A. Post-genomic era in agriculture and veterinary science: successful and proposed application of genetic targeting technologies. Front. Vet. Sci., 2023, 10:1180621 CrossRef
  17. Doudna J.A., Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science, 2014, 346(6213): 1258096 CrossRef
  18. Gladue D.P., Borca M.V. Recombinant ASF live attenuated virus strains as experimental vaccine candidates. Viruses, 2022, 14(5): 878 CrossRef
  19. Borca M.V., Berggren K.A., Ramirez-Medina E., Vuono E.A., Gladue D.P. CRISPR/Cas Gene editing of a large DNA virus: African swine fever virus. Bio-protocol, 2018, 8(16): e2978 CrossRef
  20. Borca M.V., Ramirez-Medina E., Silva E., Vuono E., Rai A., Pruitt S., Espinoza N., Velazquez-Salinas L., Gay C.G., Gladue D.P. ASFV-G-∆I177L as an effective oral nasal vaccine against the Eurasia strain of Africa swine fever. Viruses, 2021, 13(5): 765 CrossRef
  21. Schulz K., Schulz J., Staubach C., Blome S., Nurmoja I., Conraths F.J., Sauter-Louis C., Viltrop A. African swine fever re-emerging in Estonia: the role of seropositive wild boar from an epidemiological perspective. Viruses, 2021, 13(11): 2121 CrossRef
  22. Price A.A., Sampson T.R., Ratner H.K., Grakoui A., Weiss D.S. Cas9-mediated targeting of viral RNA in eukaryotic cells. Proc. Natl. Acad. Sci. USA, 2015, 112(19): 6164-6169 CrossRef
  23. Li W., Lei M., Li Z., Li H., Liu Z., He Q., Luo R. Development of a genetically engineered bivalent vaccine against porcine epidemic diarrhea virus and porcine rotavirus. Viruses, 2022, 14(8): 1746 CrossRef
  24. Gileadi O. Recombinant protein expression in E. coli: a historical perspective. Methods and Protocols, 2017, 1586: 3-10 CrossRef
  25. Chambers A.C., Aksular M., Graves L.P., Irons S.L., Possee R.D., King L.A. Overview of the baculovirus expression system. Current Protocols in Protein Science, 2018, 91: 5.4.1-5.4.6 CrossRef
  26. Ma Y., Liu Z., Hao L., Wu J., Qin B., Liang Z., Ma J., Ke H., Yang H., Li Y., Cao J. Oral vaccination using Artemia coated with recombinant Saccharomyces cerevisiae expressing cyprinid herpesvirus-3 envelope antigen induces protective immunity in common carp (Cyprinus carpio var. Jian) larvae. Research in Veterinary Science, 2020, 130: 184-192 CrossRef
  27. Karbalaei M., Rezaee S.A., Farsiani H. Pichia pastoris: a highly successful expression system for optimal synthesis of heterologous proteins. Journal of Cellular Physiology, 2020, 235(9): 5867-5881 CrossRef
  28. Pose A.G., Morell N.O., Matos D.A., Rodríguez E.R., Rodríguez E.S., Cordero L.R., Moltó M.P.R., Ramos E.M.G., Gutiérrez A.Á., Pérez L.G., Gómez J.N., Redondo A.V., Nordelo C.B. Stable lentiviral transformation of CHO cells for the expression of the hemagglutinin H5 of avian influenza virus in suspension culture. Biotechnol. Rep. (Amst.), 2014, 3: 108-116 CrossRef
  29. Raran-Kurussi S., Waugh D.S. Expression and Purification of recombinant proteins in Escherichia coli with a His6 or Dual His6-MBP Tag. Protein Crystallography: Methods and Protocols, 2017, 1607: 1-15 CrossRef
  30. Goatley L.C., Reis A.L., Portugal R., Goldswain H., Shimmon G.L., Hargreaves Z., Ho C.S., Montoya M., Sánchez-Cordón P.J., Taylor G., Dixon L.K., Netherton C.L. A pool of eight virally vectored African swine fever antigens protect pigs against fatal disease. Vaccines, 2020, 8(2): 234 CrossRef
  31. Petrov R.V., Khaitov R.M. Immunogeny i vaktsiny novogo pokoleniya [Immunogens and new generation vaccines]. Moscow, 2011 (in Russ.).
  32. Palya V., Kiss I., Tatár-Kis T., Mató T., Felföldi B., Gardin Y. Advancement in vaccination against Newcastle disease: recombinant HVT NDV provides high clinical protection and reduces challenge virus shedding with the absence of vaccine reactions. Avian Dis., 2012, 56(2): 282-287 CrossRef
  33. Zanetti F., Rudak L., Micucci M., Grand D.C., Luque A., Russo S., Taboga O., Pérez O., Calamante G. Development and preliminary assessment of a recombinant canarypox virus as an antirabic vaccine candidate. Rev. Argent. Microbiol., 2012, 44(2): 75-84.
  34. Palgen J.L., Feraoun Y., Dzangué-Tchoupou G., Joly C., Martinon F., Le Grand R., Beignon A.S. Optimize prime/boost vaccine strategies: trained immunity as a new player in the game. Front. Immunol., 2021, 12: 612747 CrossRef
  35. Bai H., Lester G.M.S., Petishnok L.C., Dean D.A. Cytoplasmic transport and nuclear import of plasmid DNA. Biosci. Rep., 2017, 37(6): BSR20160616 CrossRef
  36. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., Felgner P.L. Direct gene transfer into mouse muscle in vivo. Science, 1990, 247(4949 Pt 1): 1465-1468 CrossRef
  37. Wolff J.A., Ludtke J.J., Acsadi G., Williams P., Jani A. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum. Mol. Genet.,1992, 1: 363-369 CrossRef
  38. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., Gromkowski S.H., Deck R.R., DeWitt C.M., Friedman A., Hawe L.A. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science, 1993, 259(5102): 1745-1749 CrossRef
  39. Qin F., Xia F., Chen H., Cui B., Feng Y., Zhang P., Chen J., Luo M. A guide to nucleic acid vaccines in the prevention and treatment of infectious diseases and cancers: from basic principles to current applications. Front. Cell. Dev. Biol., 2021, 9: 633776 CrossRef
  40. Porter K.R., Raviprakash K. DNA vaccine delivery and improved immunogenicity. Curr. Issues Mol. Biol.,2017, 22: 129-138 CrossRef
  41. Hobernik D., Bros M. DNA vaccines — how far from clinical use? Int. J. Mol. Sci., 2018, 19(11): 3605 CrossRef
  42. Caracciolo G., Amenitsch H. Cationic liposome/DNA complexes: from structure to interactions with cellular membranes. Eur. Biophys. J., 2012, 41(10): 815-829 CrossRef
  43. Belov S.Yu. Razrabotka sistemy dostavki geneticheskogo materiala s ispol’zovaniem mikrosfer. Avtoreferat kandidatskoy dissertatsii[Development of a genetic material delivery system using microspheres. PhD Thesis]. Pokrov, 2011 (in Russ.).
  44. Dalmo R.A. DNA vaccines for fish: Review and perspectives on correlates of protection. J. Fish Dis., 2018, 41: 1-9 (doi: 10.1111/jfd.12727">CrossRef
  45. CDC-Media Relations-Press Release. CDC and Fort Dodge Animal Health Achieve First Licensed DNA Vaccine. Available: https://www.cdc.gov/media/pressrel/r050718.htm. Accessed: 10/10/2022. 
  46. Wheeler S.S., Langevin S., Woods L., Carroll B.D., Vickers W., Morrison S.A., Chang G.-J.J., Reisen W.K., Boyce W.M. Efficacy of three vaccines in protecting Western Scrub-Jays (Aphelocoma californica) from experimental infection with West Nile virus: implications for vaccination of Island Scrub-Jays (Aphelocoma insularis). Vector Borne Zoonotic Dis., 2011, 11: 1069-1080 CrossRef
  47. Liu M.A. A comparison of plasmid DNA and mRNA as vaccine technologies. Vaccines (Basel), 2019, 7(2): 37 CrossRef
  48. Pardi N., Hogan M.J., Porter F.W., Weissman D. mRNA vaccines — a new era in vaccinology. Nat. Rev. Drug Discov., 2018, 17(4): 261-279 CrossRef
  49. Cho S.W., Shin S.C., Nam Y., Ahn H.J. A T7 autogene-mediated DNA vaccine platform for SARS-CoV-2: Overcoming DNA vaccine limitations with enhanced spike mRNA production. J Control Release, 2025, 24:113776 CrossRef
  50. Schnee M., Vogel A.B., Voss D., Petsch B., Baumhof P., Kramps T., Stitz L. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl. Trop. Dis., 2016, 10(6): e0004746 CrossRef
  51. Le T., Sun C., Chang J., Zhang G., Yin X. mRNA vaccine development for emerging animal and zoonotic diseases. Viruses, 2022, 14(2): 401 CrossRef
  52. Chernyshev R.S., Sprygin A.V., Igolkin A.S., Zhbanova T.V., Perevozchikova N.A., Romenskaya D.V., Gruzdev K.N., Mazloum A. Current approaches to the vaccine development for African swine fever (review).Sel'skokhozyaistvennaya biologiya [Agricultural Biology], 2022, 57(4): 609-627 CrossRef
  53. Monteagudo P.L., Lacasta A., López E., Bosch L., Collado J., Pina-Pedrero S., Correa-Fiz F., Accensi F., Navas M.J., Vidal E., Bustos M.J., Rodríguez J.M., Gallei A., Nikolin V., Salas M.L., Rodríguez F. BA71ΔCD2: a new recombinant live attenuated African swine fever virus with cross-protective capabilities. Journal of Virology, 2017, 91(21): e01058-17 CrossRef
  54. Lopez E., van Heerden J., Bosch-Camós L., Accensi F., Navas M.J., López-Monteagudo P., Argilaguet J., Gallardo C., Pina-Pedrero S., Salas M.L., Salt J., Rodriguez F. Live attenuated African swine fever viruses as ideal tools to dissect the mechanisms involved in cross-protection. Viruses, 2020, 12(12): 1474 CrossRef
  55. Reis A.L., Goatley L.C., Jabbar T., Sanchez-Cordon P.J., Netherton C.L., Chapman D.A.G., Dixon L.K. Deletion of the African swine fever virus gene DP148R does not reduce virus replication in culture but reduces virus virulence in pigs and induces high levels of protection against challenge. Journal of Virology, 2017, 91(24): e01428-17 CrossRef
  56. Wu L., Yang B., Yuan X., Hong J., Peng M., Chen J.L., Song Z. Regulation and evasion of host immune response by African swine fever virus. Frontiers in Microbiology, 2021, 12: 698001 CrossRef
  57. Gallardo C., Sánchez E.G., Pérez-Núñez D., Nogal M., de León P., Carrascosa Á.L., Nieto R., Soler A., Arias M.L., Revilla Y. African swine fever virus (ASFV) protection mediated by NH/P68 and NH/P68 recombinant live-attenuated viruses. Vaccine, 2018, 36(19): 2694-2704 CrossRef
  58. O’Donnell V., Holinka L.G., Gladue D.P., Sanford B., Krug P.W., Lu X., Arzt J., Reese B., Carrillo C., Risatti G.R., Borca M.V. African swine fever virus Georgia isolate harboring deletions of MGF360 and MGF505 genes is attenuated in swine and confers protection against challenge with virulent parental virus. Journal of Virology, 2015, 89(11): 6048-6056 CrossRef
  59. Chen W., Zhao D., He X., Liu R., Wang Z., Zhang X., Li F., Shan D., Chen H., Zhang J., Wang L., Wen Z., Wang X., Guan Y., Liu J., Bu Z. A seven-gene-deleted African swine fever virus is safe and effective as a live attenuated vaccine in pigs. Sci. China Life Sci,, 2020, 63(5): 623-634 CrossRef
  60. Borca M.V., Ramirez-Medina E., Silva E., Vuono E., Rai A., Pruitt S., Holinka L.G., Velazquez-Salinas L., Zhu J., Gladue D.P. Development of a highly effective African swine fever virus vaccine by deletion of the I177L gene results in sterile immunity against the current epidemic Eurasia strain. Journal of Virology, 2020, 94: e02017-19 CrossRef
  61. Borca M.V., Rai A., Ramirez-Medina E., Silva E., Velazquez-Salinas L., Vuono E., Pruitt S., Espinoza N., Gladue D.P. A cell culture-adapted vaccine virus against the current African swine fever virus pandemic strain. Journal of Virology, 2021, 95(14): e0012321 CrossRef
  62. Tran X.H., Le T.T.P., Nguyen Q.H., Do T.T., Nguyen V.D., Gay C.G., Borca M.V., Gladue D.P. African swine fever virus vaccine candidate ASFV-G-ΔI177L efficiently protects European and native pig breeds against circulating Vietnamese field strain. Transboundary and Emerging Diseases, 2021, 69: e497-e504 CrossRef
  63. Reuters. Vietnam develops 'world's first' African swine fever vaccine for commercial use. Available: https://www.reuters.com/business/healthcare-pharmaceuticals/vietnam-develops-worlds-first-african-swine-fever-vaccine-commercial-use-2022-06-01/. Accessed: 10/16/2022.
  64. Mai T.N., Sekiguchi S., Huynh T.M.L., Cao T.B.P., Le V.P., Dong V.H., Vu V.A., Wiratsudakul A. Dynamic models of within-herd transmission and recommendation for vaccination coverage requirement in the case of African swine fever in Vietnam. Vet. Sci., 2022, 9(6): 292 CrossRef
  65. Veterinariya i zhizn’. V’etnam priostanavlivaet ispol’zovanie vaktsiny protiv AChS iz-za massovogo padezha immunizirovannykh sviney [Veterinary and life. Vietnam suspends use of ASF vaccine due to mass deaths of immunized pigs]. Available:  https://vetandlife.ru/so-bytiya/vetnam-priostanavlivaet-ispolzovanie-vakciny-protiv-achs-iz-za-massovogo-padezha-immunizirovannyh-svinej/?ysclid=lijt21snem453001676. Accessed: 06/06/2023 (in Russ.).
  66. Ramirez-Medina E., Vuono E., Silva E., Rai A., Valladares A., Pruitt S., Espinoza N., Velazquez-Salinas L., Borca M.V., Gladue D.P. Evaluation of the deletion of MGF110-5L-6L on swine virulence from the pandemic strain of African swine fever virus and use as a DIVA marker in vaccine candidate ASFV-G-ΔI177L. J. Virol., 2022, 96(14): e0059722 CrossRef
  67. Zhang Y., Ke J., Zhang J., Yang J., Yue H., Zhou X., Qi Y., Zhu R., Miao F., Li Q., Zhang F., Wang Y., Han X., Mi L., Yang J., Zhang S., Chen T., Hu R. African swine fever virus bearing an I226R gene deletion elicits robust immunity in pigs to African swine fever. Journal of Virology, 2021, 95(23): e0119921 CrossRef
  68. Hong J., Chi X., Yuan X., Wen F., Rai K.R., Wu L., Song Z., Wang S., Guo G., Chen J.L. I226R Protein of African swine fever virus is a suppressor of innate antiviral responses. Viruses, 2022, 14(3): 575 CrossRef
  69. Carrascosa A.L., Sastre I., Viñuela E. Production and purification of recombinant African swine fever virus attachment protein p12.Journal of Biotechnology, 1995, 40(2): 73-86 CrossRef
  70. Ruiz-Gonzalvo F., Rodríguez F., Escribano J.M. Functional and immunological properties of the baculovirus-expressed hemagglutinin of African swine fever virus. Virology, 1996, 218(1): 285-289 CrossRef
  71. Gómez-Puertas P., Rodríguez F., Oviedo J.M., Brun A., Alonso C., Escribano J.M. The African swine fever virus proteins p54 and p30 are involved in two distinct steps of virus attachment and both contribute to the antibody-mediated protective immune response. Virology, 1998, 243(2): 461-471 CrossRef
  72. Neilan J.G., Zsak L., Lu Z., Burrage T.G., Kutish G.F., Rock D.L. Neutralizing antibodies to African swine fever virus proteins p30, p54, and p72 are not sufficient for antibody-mediated protection. Virology, 2004, 319(2): 337-342 CrossRef
  73. Barderas M.G., Rodríguez F., Gómez-Puertas P., Avilés M., Beitia F., Alonso C., Escribano J.M. Antigenic and immunogenic properties of a chimera of two immunodominant African swine fever virus proteins. Archives of Virology, 2001, 146(9): 1681-1691 CrossRef
  74. Goatley L.C., Reis A.L., Portugal R., Goldswain H., Shimmon G.L., Hargreaves Z., Ho C.S., Montoya M., Sánchez-Cordón P.J., Taylor G., Dixon L.K., Netherton C.L. A pool of eight virally vectored African swine fever antigens protect pigs against fatal disease. Vaccines, 2020, 8(2): 234 CrossRef
  75. Boinas F., Hutchings G., Dixon L., Wilkinson P. Characterization of pathogenic and non-pathogenic African swine fever virus isolates from Ornithodoros erraticus inhabiting pig premises in Portugal. J. Gen. Virol., 2004, 85: 2177-2187 CrossRef
  76. Jancovich J.K., Chapman D., Hansen D.T., Robida M.D., Loskutov A., Craciunescu F., Borovkov A., Kibler K., Goatley L., King K., Netherton C.L., Taylor G., Jacobs B., Sykes K., Dixon L.K. Immunization of pigs by DNA prime and recombinant vaccinia virus boost to identify and rank African swine fever virus immunogenic and protective proteins. Journal of Virology, 2018, 92(8): e02219-17 CrossRef
  77. Imatdinov A.R., Dubrovskaya O.A., Morozova D.Yu., Lyska V.M., Sereda A.D. The study of antigenicity, immunogenicity and protective potential of dna constructs containing fragments of genes CP204L, E183L OR EP402R of African swine fever virus strain MK-200. Sel'skokhozyaistvennaya biologiya [Agricultural Biology], 2018, 53(4): 860-867 CrossRef
  78. Sereda A.D., Kazakova A.S., Imatdinov A.R., Kolbasov D.V. Humoral and cell immune mechanisms under African swine fever (review) Sel'skokhozyaistvennaya biologiya [Agricultural Biology], 2015, 50(6): 709-718 CrossRef (in Engl.). 
  79. Nie Z., Zhu S., Wu L., Sun R., Shu J., He Y., Feng H. Progress on innate immune evasion and live attenuated vaccine of pseudorabies virus. Front. Microbiol., 2023, 14: 1138016 CrossRef
  80. Bartha A. Experiments to reduce the virulence of Aujeszky’s virus (in Hungarian). Magyar Állatorvosok Lapja, 1961, 16: 42-45.
  81. Christensen L.S., Medveczky I., Strandbygaard B.S., Pejsak Z. Characterization of field isolates of suid herpesvirus 1 (Aujeszky's disease virus) as derivatives of attenuated vaccine strains. Arch. Virol., 1992, 124(3-4): 225-234 CrossRef
  82. Zuckermann F.A., Mettenleiter T.C., Schreurs C., Sugg N., Ben-Porat T. Complex between glycoproteins gI and gp63 of pseudorabies virus: its effect on virus replication. J. Virol., 1988, 62(12): 4622-4626 CrossRef
  83. Geck P., Medveczky I., Lomniczi B. Relation of the Bartha'’s vaccine strain and other avirulent Aujeszky’s disease virus strains isolated from field cases. Magyar Allatorvosok Lapja (Hungary), 1982, 37: 657-661.
  84. Kimman T.G., De Wind N., Oei-Lie N., Pol J.M.A., Berns A.J.M., Gielkens A.L.J. Contribution of single genes within the unique short region of Aujeszky’s disease virus (Suid herpesvirus type 1) to virulence, pathogenesis and immunogenicity. J. Gen. Virol., 1992, 73: 243-251.
  85. Gusev A.A., Diev V.I., Zakharov V.M., Konstantinov A.V., Morenkov O.S., Ulasov V.I., Blotova G.A., Mikhalishin V.V. Markirovannaya virusvaktsina protiv bolezni Aueski. Patent № 2242247 C2 (RF), MPK A61K 39/245, A61P 31/12, C12N 7/00. Federal’noe gosudarstvennoe uchrezhdenie Vserossiyskiy nauchno-issledovatel’skiy institut zashchity zhivotnykh. № 2003100456/13. Zayavl. 05.01.2003. Opubl. 20.12.2004 [Marked virus vaccine against Aujeszky's disease. Patent No. 2242247 C2 (RF), IPC A61K 39/245, A61P 31/12, C12N 7/00. Federal State Institution All-Russian Research Institute for Animal Protection. No. 2003100456/13. Claimed 01/05/2003. Publ. 12/20/2004] (in Russ.).
  86. Baborenko E.P. Veterinariya segodnya, 2016, 4(19): 49-52 in Russ.">CrossRef
  87. Xu A., Qin C., Lang Y., Wang M., Lin M., Li C., Zhang R., Tang J. A simple and rapid approach to manipulate pseudorabies virus genome by CRISPR/Cas9 system. Biotechnol. Lett., 2015, 37(6): 1265-1272 CrossRef
  88. Liang X., Sun L., Yu T., Pan Y., Wang D., Hu X., Fu Z., He Q., Cao G. A CRISPR/Cas9 and Cre/Lox system-based express vaccine development strategy against re-emerging Pseudorabies virus. Sci. Rep., 2016, 6: 19176 CrossRef
  89. Mikulska-Skupień E., Szweda W., Procajło Z. Evaluation of specific humoral immune response in pigs vaccinated intradermally with deleted Aujeszky's disease vaccine and challenged with virulent strain of Herpesvirus suis type 1. Pol. J. Vet. Sci., 2005, 8(1): 11-16.
  90. Schang L.M., Kutish G.F., Osorio F.A. Correlation between precolonization of trigeminal ganglia by attenuated strains of pseudorabies virus and resistance to wild-type virus latency. J. Virol., 1994, 68(12): 8470-8476 CrossRef
  91. Maala K.U., Fang S.Kh., Yao Zh.S., Zhu L.D., Lising R.T., Yang K.Ya. Svinovodstvo, 2012, 7: 55-56 (in Russ.).
  92. Fan J., Liao Y., Zhang M., Liu C., Li Z., Li Y., Li X., Wu K., Yi L., Ding H., Zhao M., Fan S., Chen J. Anti-slassical swine fever virus strategies. Microorganisms, 2021, 9(4): 761 CrossRef
  93. Blome S., Staubach C., Henke J., Carlson J., Beer M. Classical Swine Fever — an updated review. Viruses, 2017, 9(4): 86 CrossRef
  94. OIE — World Organization for Animal Health. Terrestrial Animal Health Code. Chapter 15.2: Infection with classical swine fever virus. Available: https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/?id=169&L=1&htmfile=chapit-re_csf.htm. Accessed: 11/02/2022.
  95. Maurer R., Stettler P., Ruggli N., Hofmann M.A., Tratschin J.D. Oronasal vaccination with classical swine fever virus (CSFV) replicon particles with either partial or complete deletion of the E2 gene induces partial protection against lethal challenge with highly virulent CSFV. Vaccine, 2005, 23(25): 3318-3328 CrossRef
  96. Frey C.F., Bauhofer O., Ruggli N., Summerfield A., Hofmann M.A., Tratschin J.D. Classical swine fever virus replicon particles lacking the Erns gene: a potential marker vaccine for intradermal application. Vet. Res., 2006, 37(5): 655-670 CrossRef
  97. Smith G.E., Summers M.D., Fraser M.J. Production of human beta interferon in insect cells infected with a baculovirus expression vector. Mol. Cell Biol., 1983, 3(12): 2156-2165 CrossRef
  98. Grebennikova T.V., Zaberezhnyy A.D., Bogdanova V.S., Krivonos A.V., Tsibezov V.V., Dudnikov L.A. Voprosy virusologii, 2000, 45(2): 36-41 (in Russ.).
  99. Alekseev K.P., Raev S.A., Yuzhakov A.G., Verkhovskiy O.A., Zaberezhnyy A.D., Aliper T.I. Trudy Federal’nogo tsentra okhrany zdorov’ya zhivotnykh, 2018, 16: 293-305 (in Russ.">CrossRef
  100. Alekseev K.P., Raev S.A., Yuzhakov A.G., Shemelkov E.V., Latyshev O.E., Eliseeva O.V., Kostina L.V., Tsibezov V.V., Stafford V.V., Kunakov K.Yu., Verkhovsky O.A., Zaberezhny A.D., Aliper T.I. Experimental subunit vaccine against classical swine fever development and trial. Sel'skokhozyaistvennayabiologiya[AgriculturalBiology], 2019, 54(6): 1236-1246 CrossRef
  101. Li F., Li B., Niu X., Chen W., Li Y., Wu K., Li X., Ding H., Zhao M., Chen J., Yi L. The Development of classical swine fever marker vaccines in recent years. Vaccines (Basel), 2022, 10(4): 603 CrossRef
  102. Gong W., Li J., Wang Z., Sun J., Mi S., Xu J., Cao J., Hou Y., Wang D., Huo  X., Sun Y. Commercial E2 subunit vaccine provides full protection to pigs against lethal challenge with 4 strains of classical swine fever virus genotype 2. Vet. Microbiol., 2019, 237: 108403 CrossRef
  103. Katorkina E.I., Tsybanov S.Zh., Malogolovkin A.S. Results of Fc-protein fusion technology application for vaccine design against infectious diseases of animals and human (review). Sel'skokhozyaistvennaya biologiya [Agricultural Biology], 2019, 54(4): 642-654 CrossRef
  104. Chen K.J., Lee C.K. Self-cleaved expression of recombinant lysostaphin from its cellulose binding domain fusion. Appl. Microbiol. Biotechnol., 2022, 106(13-16): 5023-5033 CrossRef
  105. Sohn E.J., Lee Y., Park N., Park M., Kim N.H., Park S., Min K., Gu S., Park Y., Song J., An D.J. Development of plant-produced E2 protein for use as a green vaccine against classical swine fever virus. J. Plant Biol., 2018, 61: 241-252 CrossRef
  106. Park Y., An D.J., Choe S., Lee Y., Park M., Park S., Gu S., Min K., Kim N.H., Lee S., et al. Development of recombinant protein-based vaccine against classical swine fever virus in pigs using transgenic Nicotiana benthamiana. Front. Plant Sci., 2019, 10: 624 CrossRef
  107. Laughlin R.C., Madera R., Peres Y., Berquist B.R., Wang L., Buist S., Burakova Y., Palle S., Chung C.J., Rasmussen M.V., Martel E., Brake D.A., Neilan J.G., Lawhon S.D., Adams L.G., Shi J., Marcel S. Plant-made E2 glycoprotein single-dose vaccine protects pigs against classical swine fever. Plant Biotechnol. J., 2019, 17: 410-420 CrossRef
  108. Park Y., Lee S., Kang H., Park M., Min K., Kim N.H., Gu S., Kim J.K., An D.J., Choe S.,Sohn E.J. A classical swine fever virus E2 fusion protein produced in plants elicits a neutralizing humoral immune response in mice and pigs. Biotechnol Lett., 2020, 42(7): 1247-1261 CrossRef
  109. Xu Y.G., Guan X.T., Liu Z.M., Tian C.Y., Cui L.C. Immunogenicity in swine of orally administered recombinant Lactobacillus plantarum expressing classical swine fever virus E2 protein in conjunction with thymosin a-1 as an adjuvant. Appl. Environ. Microbiol., 2015, 81(11): 3745-3752 CrossRef
  110. Sun Y., Liu D.F., Wang Y.F., Liang B.B., Cheng D., Li N., Qi Q.F., Zhu Q.H., Qiu, H.J. Generation and efficacy evaluation of a recombinant adenovirus expressing the E2 protein of classical swine fever virus. Res. Vet. Sci., 2010, 88: 77-82 CrossRef
  111. Li N., Zhao J.J., Zhao H.P., Sun Y., Zhu Q.H., Tong G.Z., Qiu H.J. Protection of pigs from lethal challenge by a DNA vaccine based on an alphavirus replicon expressing the E2 glycoprotein of classical swine fever virus. J. Virol. Methods, 2007, 144: 73-78 CrossRef
  112. Sun Y., Li H.Y., Tian D.Y., Han Q.Y., Zhang X., Li N., Qiu H.J. A novel alphavirus replicon-vectored vaccine delivered by adenovirus induces sterile immunity against classical swine fever. Vaccine, 2011, 29: 8364-8372 CrossRef
  113. Sun Y., Tian D.Y., Li S., Meng Q.L., Zhao B.B., Li Y., Li D., Ling L.J., Liao Y.J., Qiu H.J. Comprehensive evaluation of the adenovirus/alphavirus-replicon chimeric vector-based vaccine rAdV-SFV-E2 against classical swine fever. Vaccine, 2013, 31: 538-544 CrossRef
  114. Cong X., Lei J.L., Xia S.L., Wang Y.M., Li Y., Li S., Luo Y., Sun Y., Qiu H.J. Pathogenicity and immunogenicity of a gE/gI/TK gene-deleted pseudorabies virus variant in susceptible animals. Vet. Microbiol., 2016, 182: 170-177 CrossRef
  115. Lei J.L., Xia S.L., Wang Y., Du M., Xiang G.T., Cong X., Luo Y., Li L.F., Zhang L., Yu J., Hu Y., Qiu H.J., Sun Y. Safety and immunogenicity of a gE/gI/TK gene-deleted pseudorabies virus variant expressing the E2 protein of classical swine fever virus in pigs. Immunol. Lett., 2016, 174: 63-71 CrossRef
  116. Abid M., Teklue T., Li Y., Wu H., Wang T., Qiu H.J., Sun Y. Generation and immunogenicity of a recombinant pseudorabies virus co-expressing classical swine fever virus E2 protein and porcine circovirus type 2 capsid protein based on fosmid library platform. Pathogens, 2019, 8(4): 279 CrossRef
  117. Gao F., Jiang Y., Li G., Zhou Y., Yu L., Li L., Tong W., Zheng H., Zhang Y., Yu H., Shan T., Yang S., Liu H., Zhao K., Tong G. Porcine reproductive and respiratory syndrome virus expressing E2 of classical swine fever virus protects pigs from a lethal challenge of highly-pathogenic PRRSV and CSFV. Vaccine, 2018, 36(23): 3269-3277 CrossRef
  118. Gao F., Jiang Y., Li G., Li L., Zhang Y., Yu L., Zheng H., Tong W., Zhou Y., Liu C., Shan T., Yu H., Kong N., Chen P., Tong G. Evaluation of immune efficacy of recombinant PRRSV vectored vaccine rPRRSV-E2 in piglets with maternal derived antibodies. Vet. Microbiol., 2020, 248: 108833 CrossRef
  119. Lin H., Ma Z., Chen L., Fan H. Recombinant swinepox virus expressing glycoprotein E2 of classical swine fever virus confers complete protection in pigs upon viral challenge. Front. Vet. Sci., 2017, 4: 81 CrossRef
  120. Blome S., Wernike K., Reimann I., König P., Moß C., Beer M. A decade of research into classical swine fever marker vaccine CP7_E2alf (Suvaxyn® CSF Marker): a review of vaccine properties. Vet. Res., 2017, 48(1): 51 CrossRef
  121. Blome S., Gabriel C., Schmeiser S., Meyer D., Meindl-Böhmer A., Koenen F., Beer M. Efficacy of marker vaccine candidate CP7_E2alf against challenge with classical swine fever virus isolates of different genotypes. Vet. Microbiol., 2014, 169(1-2): 8-17 CrossRef
  122. Meyer D., Loeffen W., Postel A., Fritsche S., Becher P. Reduced specificity of Erns antibody ELISAs for samples from piglets with maternally derived antibodies induced by vaccination of sows with classical swine fever marker vaccine CP7_E2alf. Transbound. Emerg. Dis., 2018, 65(2): e505-e508 CrossRef
  123. van Gennip H.G., van Rijn P.A., Widjojoatmodjo M.N., de Smit A.J., Moormann R.J. Chimeric classical swine fever viruses containing envelope protein E(RNS) or E2 of bovine viral diarrhoea virus protect pigs against challenge with CSFV and induce a distinguishable antibody response. Vaccine, 2000, 19(4-5): 447-459 CrossRef
  124. Streck A.F., Canal C.W., Truyen U. Molecular epidemiology and evolution of porcine parvoviruses. Infect. Genet. Evol., 2015, 36: 300-306 CrossRef
  125. Garcia-Morante B., Noguera M., Klocke S., Sommer K., Kaiser T., Haist V., Schmidt H., Bridger P. A novel subunit vaccine based on the viral protein 2 of porcine parvovirus: safety profile in bred pigs at different stages of the reproduction cycle and in offspring. Heliyon, 2019, 5(11): e02593 CrossRef
  126. Ling Z., Zhang H., Chen Y., Sun L., Zhao J. A subunit vaccine based on the vp2 protein of porcine parvovirus 1 induces a strong protective effect in pregnant gilts. Vaccines (Basel), 2023, 11(11): 1692 CrossRef
  127. Mészáros I., Olasz F., Cságola A., Tijssen P., Zádori Z. Biology of porcine parvovirus (Ungulate parvovirus 1). Viruses, 2017, 9(12): 393 CrossRef
  128. Antonis A.F., Bruschke C.J., Rueda P., Maranga L., Casal J.I., Vela C., Hilgers L.A., Belt P.B., Weerdmeester K., Carrondo M.J., Langeveld J.P. A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure. Vaccine, 2006, 24(26): 5481-5490 CrossRef
  129. Paul P.S., Mengeling W.L. Oronasal and intramuscular vaccination of swine with a modified live porcine parvovirus vaccine: multiplication and transmission of the vaccine virus. American Journal of Veterinary Research, 1984, 45(12): 2481-2485.
  130. Hong Q., Qian P., Li X.M., Yu X.L., Chen H.C. A recombinant pseudorabies virus co-expressing capsid proteins precursor P1-2A of FMDV and VP2 protein of porcine parvovirus: a trivalent vaccine candidate. Biotechnol. Lett., 2007, 29(11): 1677-1683 CrossRef
  131. European Medicines Agency. ReproCyc ParvoFLEX. Available: https://www.ema.eur-opa.eu/en/medicines/veterinary/EPAR/reprocyc-parvoflex. Accessed: 12/27/2022.
  132. Garcia-Morante B., Noguera M., Kraft C., Bridger P. Field evaluation of the safety and compatibility of a combined vaccine against porcine parvovirus 1 and porcine reproductive and respiratory syndrome virus in breeding animals. Porcine Health Manag., 2019, 5: 28 CrossRef
  133. Garcia-Morante B., Noguera M., Klocke S., Sommer K., Bridger P. Duration of immunity against heterologous porcine parvovirus 1 challenge in gilts immunized with a novel subunit vaccine based on the viral protein 2. BMC Vet. Res., 2020, 16(1): 184 CrossRef
  134. Orlyankin B.G., Aliper T.I. Veterinariya, 2021, 8: 3-10 CrossRef (in Russ.).
  135. Keep S., Carr B.V., Lean F.Z.X., Fones A., Newman J., Dowgier G., Freimanis G., Vatzia E., Polo N., Everest H., Webb I., Mcnee A., Paudyal B., Thakur N., Nunez A., MacLoughlin R., Maier H., Hammond J., Bailey D., Waters R., Charleston B., Tuthill T., Britton P., Bickerton E., Tchilian E. Porcine respiratory coronavirus as a model for acute respiratory coronavirus disease. Front. Immunol., 2022, 13: 867707 CrossRef
  136. Callebaut P., Pensaert M. Expression and immunogenicity of the spike glycoprotein of porcine respiratory coronavirus encoded in the E3 region of adenovirus. In: Corona- and related viruses. Advances in Experimental Medicine and Biology /P.J. Talbot, G.A. Levy (eds.), 1995, 380 CrossRef
  137. Turlewicz-Podbielska H., Pomorska-Mól M. Porcine coronaviruses: overview of the state of the art. Virol. Sin., 2021, 36: 833-851 CrossRef
  138. Chen K., Zhao K., He W., Gao W., Zhao C., Wang L., Pan W., Song D., Wang C., Gao F. Comparative evaluation of two hemagglutinating encephalomyelitis coronavirus vaccine candidates in mice. Clinical and Vaccine Immunology CVI, 2012, 19(7): 1102-1109 CrossRef
  139. Zhang Y., Han L., Xia L., Yuan Y., Hu, H. Assessment of hemagglutination activity of porcine deltacoronavirus.Journal of Veterinary Science, 2020, 21(1): e12 CrossRef
  140. Tang P., Cui E., Song Y., Yan R., Wang J. Porcine deltacoronavirus and its prevalence in China: a review of epidemiology, evolution, and vaccine development. Archives of Virology, 2021, 166(11): 2975-2988 CrossRef
  141. Huang Y., Xu Z., Gu S., Nie M., Wang Y., Zhao J., Li F., Deng H., Huang J., Sun X., Zhu L. The recombinant pseudorabies virus expressing porcine deltacoronavirus spike protein is safe and effective for mice. BMC Vet. Res., 2022, 18(1): 16 CrossRef
  142. Duan C. An updated review of porcine deltacoronavirus in terms of prevalence, pathogenicity, Pathogenesis and antiviral strategy. Front. Vet. Sci., 2022, 8: 811187 CrossRef
  143. Kukharkina O.V., Borisova O.A. Trudy Federal’nogo tsentra okhrany zdorov’ya zhivotnykh, 2015, 13: 69-88 (in Russ.).
  144. Liu D.Q., Ge J.W., Qiao X.Y., Jiang Y.P., Liu S.M., Li Y.J. High-level mucosal and systemic immune responses induced by oral administration with Lactobacillus-expressed porcine epidemic diarrhea virus (PEDV) S1 region combined with Lactobacillus-expressed N protein. Appl. Microbiol Biotechnol., 2012, 93(6): 2437-2446 CrossRef
  145. Meng F., Ren Y., Suo S., Sun X., Li X., Li P., Yang W., Li G., Li L., Schwegmann-Wessels C., Herrler G., Ren X. Evaluation on the efficacy and immunogenicity of recombinant DNA plasmids expressing spike genes from porcine transmissible gastroenteritis virus and porcine epidemic diarrhea virus. PLoS ONE, 2013, 8(3): e57468 CrossRef
  146. Bae J.L., Lee J.G., Kang T.J., Jang H.S., Jang Y.S., Yang M.S. Induction of antigen-specific systemic and mucosal immune responses by feeding animals transgenic plants expressing the antigen. Vaccine, 2003, 21(25-26): 4052-4058 CrossRef
  147. Gerdts V., Zakhartchouk A. Vaccines for porcine epidemic diarrhea virus and other swine coronaviruses. Veterinary Microbiology, 2017, 206: 45-51 CrossRef
  148. Yuan X., Lin H., Fan H. Efficacy and immunogenicity of recombinant swinepox virus expressing the A epitope of the TGEV S protein. Vaccine, 2015, 33(32): 3900-3906 CrossRef
  149. Zhao F., Liu L., Xu M., Shu X., Zheng L., Wei Z. Assessments of different inactivating reagents in formulating transmissible gastroenteritis virus vaccine. Virol. J., 2020, 17(1): 163 CrossRef
  150. Pascual-Iglesias A., Sanchez C.M., Penzes Z., Sola I., Enjuanes L., Zuñiga S. Recombinant chimeric transmissible gastroenteritis virus (TGEV)—porcine epidemic diarrhea virus (PEDV) virus provides protection against virulent PEDV. Viruses, 2019, 11(8): 682 CrossRef
  151. Tan C.Y., Lin C.N., Ooi P.T. What do we know about porcine circovirus 3 (PCV3) diagnosis so far?: A review. Transboundary and Emerging Diseases, 2021, 68(6): 2915-2935 CrossRef
  152. Zhang H.H., Hu W.Q., Li J.Y., Liu T.N., Zhou J.Y., Opriessnig T., Xiao C.T. Novel circovirus species identified in farmed pigs designated as porcine circovirus 4, Hunan province, China. Transboundary and Emerging Diseases, 2020, 67(3): 1057-1061 CrossRef
  153. Klaumann F., Correa-Fiz F., Franzo G., Sibila M., Núñez J.I., Segalés J. Current knowledge on porcine circovirus 3 (PCV-3): a novel virus with a yet unknown impact on the swine industry. Front. Vet. Sci., 2018, 5: 315 CrossRef
  154. Raev S.A., Alekseev K.P., Shemel’kov E.V., Aliper T.I., Musienko M.I., Orlyankin B.G., Mishin A.M., Verkhovskiy O.A., Zaberezhnyy A.D. Veterinariya segodnya, 2013, 3(6): 54-59 (in Russ.).
  155. Guo J., Hou L., Zhou J., Wang D., Cui Y., Feng X., Liu, J. Porcine circovirus type 2 vaccines: commercial application and research advances. Viruses, 2022, 14(9): 2005 CrossRef
  156. Bandrick M., Balasch M., Heinz A., Taylor L., King V., Toepfer J., Foss D. A bivalent porcine circovirus type 2 (PCV2), PCV2a-PCV2b, vaccine offers biologically superior protection compared to monovalent PCV2 vaccines. Vet. Res., 2022, 53(1): 12 CrossRef
  157. Hemann M., Beach N.M., Meng X.J., Wang C., Halbur P.G., Opriessnig T. A live-attenuated and an inactivated chimeric porcine circovirus (PCV)1-2 vaccine are both effective at inducing a humoral immune response and reducing PCV2 viremia and intrauterine infection in female swine of breeding age. Can. J. Vet. Res., 2014, 78(1): 8-16.
  158. Sylla S., Cong Y.L., Sun Y.X., Yang G.L., Ding X.M., Yang Z.Q., Zhou Y.L., Yang M., Wang C.F., Ding Z. Protective immunity conferred by porcine circovirus 2 ORF2-based DNA vaccine in mice. Microbiology and Immunology, 2014, 58(7): 398-408 CrossRef
  159. Hou Z., Wang H., Feng Y., Li Q., Li J. A candidate DNA vaccine encoding a fusion protein of porcine complement C3d-P28 and ORF2 of porcine circovirus type 2 induces cross-protective immunity against PCV2b and PCV2d in pigs. Virol. J., 2019, 16(1): 57 CrossRef
  160. Park C., Jeong J., Choi K., Park S.J., Kang I., Chae C. Development of porcine circovirus 2 (PCV2) open reading frame 2 DNA vaccine with different adjuvants and comparison with commercial PCV2 subunit vaccine in an experimental challenge. Can. J. Vet. Res., 2017, 81(3): 171-177.
  161. Lin H.X., Ma Z., Yang X.Q., Fan H.J., Lu C.P. A novel vaccine against porcine circovirus type 2 (PCV2) and Streptococcus equi ssp. zooepidemicus (SEZ) co-infection. Veterinary Microbiology, 2014, 171(1-2): 198-205 CrossRef
  162. Raev S.A., Alekseev K.P., Shemel’kov E.V., Bulgakov A.D., Musienko M.I., Orlyankin B.G., Verkhovskiy O.A., Aliper T.I. Rossiyskiy veterinarnyy zhurnal, 2012, 3: 17-19 (in Russ.).
  163. Puig A., Bernal I., Sabaté D., Ballarà I., Montané J., Nodar L., Angelats D., Jordà R. Comparison of effects of a single dose of MHYOSPHERE® PCV ID with three commercial porcine vaccine associations against Mycoplasma hyopneumoniae (Mhyo) and porcine circovirus type 2 (PCV2) on piglet growth during the nursery period under field conditions. Vet. Res. Commun., 2022, 46(4): 1167-1173 CrossRef
  164. Chen X., Pan J., Huang L., Zhao M. Research progress on the E protein of porcine reproductive and respiratory syndrome virus. Front. Microbiol., 2023, 14: 1139628 CrossRef
  165. Renukaradhya G.J., Meng X.J., Calvert J.G., Roof M., Lager K.M. Live porcine reproductive and respiratory syndrome virus vaccines: Current status and future direction. Vaccine, 2015, 33(33): 4069-4080 CrossRef
  166. Chae C. Commercial PRRS modified-live virus vaccines. Vaccines, 2021, 9(2): 185 CrossRef
  167. Charerntantanakul W. Porcine reproductive and respiratory syndrome virus vaccines: Immunogenicity, efficacy and safety aspects. World Journal of Virology, 2012, 1(1): 23–30 CrossRef
  168. Kukushkin S. Zhivotnovodstvo Rossii, 2022, 2: 26-27 (in Russ.).
  169. Rompato G., Ling E., Chen Z., Van Kruiningen H., Garmendia A.E. Positive inductive effect of IL-2 on virus-specific cellular responses elicited by a PRRSV-ORF7 DNA vaccine in swine. Veterinary Immunology and Immunopathology, 2006, 109(1-2): 151-160 CrossRef
  170. Barfoed A.M., Blixenkrone-Møller M., Jensen M.H., Bøtner A., Kamstrup S. DNA vaccination of pigs with open reading frame 1-7 of PRRS virus. Vaccine, 2004, 22(27-28): 3628-3641 CrossRef
  171. Bastos R.G., Dellagostin O.A., Barletta R.G., Doster A.R., Nelson E., Zuckermann F., Osorio F.A. Immune response of pigs inoculated with Mycobacterium bovis BCG expressing a truncated form of GP5 and M protein of porcine reproductive and respiratory syndrome virus. Vaccine, 2004, 22(3-4): 467-474 CrossRef
  172. Shen G., Jin N., Ma M., Jin K., Zheng M., Zhuang T., Lu H., Zhu G., Jin H., Jin M., Huo X., Qin X., Yin R., Li C., Li H., Li Y., Han Z., Chen Y., Jin M. Immune responses of pigs inoculated with a recombinant fowlpox virus coexpressing GP5/GP3 of porcine reproductive and respiratory syndrome virus and swine IL-18. Vaccine, 2007, 25(21): 4193-4202 CrossRef
  173. Jiang Y., Fang L., Xiao S., Zhang H., Pan Y., Luo R., Li B., Chen H. Immunogenicity and protective efficacy of recombinant pseudorabies virus expressing the two major membrane-associated proteins of porcine reproductive and respiratory syndrome virus. Vaccine, 2007, 25(3): 547-560 CrossRef
  174. Jiang W., Jiang P., Wang X., Li Y., Du Y., Wang, X. Enhanced immune responses of mice inoculated recombinant adenoviruses expressing GP5 by fusion with GP3 and/or GP4 of PRRS virus. Virus Research, 2008, 136(1-2): 50-57 CrossRef
  175. Prieto C., Martínez-Lobo F.J., Díez-Fuertes F., Aguilar-Calvo P., Simarro I., Castro J.M. Immunisation of pigs with a major envelope protein sub-unit vaccine against porcine reproductive and respiratory syndrome virus (PRRSV) results in enhanced clinical disease following experimental challenge.Veterinary Journal (London), 2011, 189(3): 323-329 CrossRef
  176. de Lima M., Kwon B., Ansari I.H., Pattnaik A.K., Flores E.F., Osorio F.A. Development of a porcine reproductive and respiratory syndrome virus differentiable (DIVA) strain through deletion of specific immunodominant epitopes. Vaccine, 2008, 26(29-30): 3594-3600 CrossRef
  177. Cui J., Techakriengkrai N., Nedumpun T., Suradhat S. Abrogation of PRRSV infectivity by CRISPR-Cas13b-mediated viral RNA cleavage in mammalian cells. Sci. Rep., 2020, 10(1): 9617 CrossRef

 

back

 


CONTENTS

 

Full article PDF (Rus)